Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00

Astria Therapeutics (NASDAQ:ATXS) had its price objective lifted by Oppenheimer from $26.00 to $28.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

ATXS has been the topic of several other reports. TD Cowen started coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, September 27th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 7.1 %

ATXS opened at $9.37 on Thursday. The company has a market capitalization of $528.75 million, a price-to-earnings ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90. The business’s fifty day simple moving average is $11.40 and its 200-day simple moving average is $10.62.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. Vanguard Group Inc. boosted its position in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Tidal Investments LLC purchased a new stake in shares of Astria Therapeutics during the first quarter worth about $1,664,000. Sofinnova Investments Inc. purchased a new stake in shares of Astria Therapeutics during the second quarter worth about $552,000. ClariVest Asset Management LLC acquired a new position in shares of Astria Therapeutics during the second quarter valued at about $731,000. Finally, Ameritas Investment Partners Inc. raised its position in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.